“If HIMS is able to generate commercial success for liraglutide, it would represent a significant milestone and validate the strength of HIMS’ brand, in our view.” ...

You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...

In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Hims & Hers Health, Inc. (NYSE:HIMS). Hims & Hers Health, Inc. (NYSE:HIMS) offers a ...

Bank of America raised its price target on Hims & Hers Health, but still thinks you should sell the stock. February saw a spike in weight loss sales at the drug compounder, but future sales of ...

noting the price HIMS has listed for the product. However, if the company can achieve commercial success with liraglutide, a drug with lower efficacy and a more concerning side effect profile ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales of a significant drug set to fade, commercial innovations are needed to maintain the company’s ...

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper ...